From: Inhaled nitric oxide as adjunctive therapy for severe malaria: a randomized controlled trial
iNO (n/N, %) | Placebo (n/N, %) | OR (95 % CI) | p value | |
---|---|---|---|---|
Mortality | ||||
Mortality, 48 h | 6/87 (6.9 %) | 8/92 (8.7 %) | 0.78 (0.26–2.3) | 0.65 |
Mortality, in hospital | 7/87 (8.0 %) | 8/92 (8.7 %) | 0.92 (0.32–2.7) | 0.88 |
Mortality, 14 days | 7/87 (8.0 %) | 9/91 (9.9 %) | 0.80 (0.28–2.2) | 0.67 |
Death or sequelae at 14 days | 12/87 (13 %) | 16/91 (14 %) | 0.75 (0.33–1.7) | 0.75 |
Mortality in strictly defined severe malariaa | 7/81 (8.6 %) | 9/88 (10 %) | 0.83 (0.29–2.3) | 0.73 |
Mortality in strictly defined cerebral malariab | 6/53 (11 %) | 8/51 (16 %) | 0.69 (0.22–2.1) | 0.51 |
Mortality in HIV | 1/4 (25 %) | 0/1 (0 %) | – | 1.0 |
Complications | ||||
Development of comac | 2/26 (7·7 %) | 0/34 (0 %) | – | 0.18 |
Deterioration of coma score | 8/86 (9·3 %) | 5/91 (5·5 %) | 1·8 (0·55–5·6) | 0.33 |
Convulsions developing or persisting >6 h after admission | 19/87 (22 %) | 13/91 (14 %) | 1.7 (0·77–3·6) | 0.19 |
Hypoglycaemia (<3 mmol/L) | 10/88 (10 %) | 17/91 (19 %) | 0.56 (0·24–1·3) | 0.12 |
Severe anaemia (<50 g/L) after admissionc | 11/35 (31 %) | 5/34 (15 %) | 2·7 (0.81–8.7) | 0.10 |
Haemoglobinuriac | 0/68 (0 %) | 3/76 (3.9 %) | 0 (0–3.6) | 0.25 |
Co-treatments | ||||
Blood transfusion | 65/87 (75 %) | 67/91 (74 %) | 1.1 (0.54–2.1) | 1.0 |
Intravenous fluids | 80/88 (91 %) | 82/91 (90 %) | 1.1 (0.40–3.0) | 1.0 |
Antibiotics (any) | 82/87 (94 %) | 80/91 (88 %) | 2.3 (0.75–6.8) | 0.19 |
Ceftriaxone | 81/87 (93 %) | 76/91 (84 %) | 2.7 (0.98–7.2) | 0.06 |
Anticonvulsant (any) | 51/87 (59 %) | 36/91 (40 %) | 2.2 (1.2–3.9) | 0.016 |
Diazepam | 40/87 (46 %) | 27/91 (30 %) | 2.0 (1.1–3.7) | 0.030 |
Phenobarbitone | 29/87 (33 %) | 23/91 (25 %) | 1.5 (0.77–2.8) | 0.25 |
Antipyretic (any) | 64/87 (74 %) | 71/91 (78 %) | 0.78 (0.39–1.6) | 0.60 |